HALIFAX, NS / ACCESSWIRE / / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended ...
GlobalData on MSN11d
Health Canada approves MedMira’s rapid test for HIV and syphilisThe test enables healthcare professionals to identify HIV-1/2 and syphilis antibodies from a single finger prick sample.
MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV
HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, ...
HALIFAX, NS / ACCESSWIRE / December 30, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2024. Corporate update During Q1 FY2025 ...
Medmira (TSE:MIR) has released an update.Don't Miss Our New Year's Offers:Discover the latest stocks recommended by top Wall Street analysts, ...
MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV
HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, on December 24, 2024, the approval from Health Canada for its Multiplo ...
During Q1 FY2025, MedMira has been continuing its regulatory work and clinical trials for its Reveal® G4 HIV-1/2 rapid test CLIA-waiver and with it made substantial progress on its FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback